News

Add-on Xeljanz controls disease as treatment for non-responding AS

Adding Xeljanz (tofacitinib) to treatment with biologic disease-modifying anti-rheumatic drugs (DMARDs) when these medications aren’t working well may help adults with ankylosing spondylitis (AS) keep their disease activity under control, a study suggests. Because the study included only a few patients, “further prospective randomized controlled trials with large…

IBD patients facing greater disease risk for forms of AS: Study

People with inflammatory bowel disease (IBD) are at significantly higher risk for various forms of spondyloarthritis (SpA), including ankylosing spondylitis (AS), a study found. But the reverse wasn’t true: Having SpA was not linked to an increased risk of developing IBD, according to the new analysis, which used genetic…

axSpA patients stayed longest on TNF inhibitor golimumab: Study

Adults with axial spondyloarthritis (axSpA) remained on golimumab longer than any other TNF inhibitor, according to a real-world analysis of medical records. Although adalimumab (marketed as Humira and biosimilars) was the most commonly prescribed first- and second-line TNF inhibitor, patients stayed with golimumab (marketed…

Poor sleep quality linked to reduced physical activity in axSpA: Study

Poor sleep quality is highly prevalent among people with axial spondyloarthritis (axSpA) who have moderate to high disease activity and who don’t practice regular physical exercise, a study from Scandinavia reports. More physical activity and greater cardiorespiratory fitness were associated with better sleep. “The extent and magnitude of reduced sleep…

Intensifying treatments for axSpA driven by MD’s perspective: Study

The decision to escalate treatment for people with highly active axial spondyloarthritis (axSpA) is mainly driven by the physician’s perspective on disease activity, a real-world study has revealed. Further research is needed to better understand these decisions and to optimize axSpA management, according to researchers in the study “…

Depression, other comorbidities linked to harsher AS symptoms

Two or more comorbidities affected nearly half of the ankylosing spondylitis (AS) patients in a large study of the disease, with the most common coexisting conditions being uveitis (eye inflammation), depression, and hypertension (high blood pressure). Those with no comorbidities were younger and had shorter disease duration, the researchers reported,…